Search

We aimed to find possible protein markers and key pathways related to bladder cancer. In total, we extracted three bladder cancer tissues and three paracancerous tissues from Jiangsu Provincial People's Hospital Urology Department, and performed mass spectrometric detection with Q Exactive. Subsequently, we screened the differentially expressed proteins in the disease group and the normal group using the LIMMA package, and performed functional enrichment analyses using DAVID. Further, we constructed protein-protein interaction (PPI) networks with Cytoscape software, and analyzed modules with ClusterONE. In total, 165 differentially expressed proteins including 19 upregulated and 146 downregulated ones were obtained. ACTA2 (Actin, Alpha 2, Smooth Muscle, Aorta), ACTN1 (Actinin, Alpha 1), and VCL (Vinculin) were significant nodes with higher degrees in the PPI network. These three nodes were also hub nodes in module 2. Besides, functional enrichment analysis suggested that ECM-receptor interaction and focal adhesion were significant pathways, and these two pathways were also enriched in three network modules. In addition, ACTN1 and VCL were enriched in the focal adhesion pathway in module 2. Thus, ACTA2, ACTN1, and VCL may play important roles in bladder cancer progression and may be protein markers for this disease. The ECM-receptor interaction pathway and the focal adhesion pathway may be involved in the progression of bladder cancer. Furthermore, ACTN1 and VCL may play roles in bladder cancer development, partly via the focal adhesion pathway.

Background: The World Health Organization (WHO) recommends monitoring changes in seroprevalence of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over time from the beginning of an epidemic to predict and plan accordingly for public health responses. At present, few domestic and foreign reports exist on the diagnosis of COVID-19 patients through serological tests. To detect and assess asymptomatic infections of COVID-19 among people in Wuhan, the epicenter of the COVID-19 pandemic in China, and provide a basis for planning an adequate public health response, we analyzed the records in a Wuhan general hospital of medical examinations mandatory for 16- to 64-year-old asymptomatic people to resume their job-related work. This retrospective study estimated the seroprevalence of IgM and IgG and compared the epidemiological characteristics of asymptomatic SARS-CoV-2- infected workers. Methods: Medical examination data were collected from the Wuhan General Hospital between March 26 and April 28, 2020. Serological tests for the presence of antibodies (IgM and IgG) against SARS-CoV-2 used a colloidal gold method. Nucleic acid sequence of viruses were detected with a fluorescent PCR method. Demographical and radiological data were collected. Statistical analyses were conducted using SPSS 20.0 software. Findings: Between March 26 and April 28, 2020, a total of 18,391 asymptomatic back-to-work participants were enrolled. Among them, 89 had positivity for IgM (0·48%, 95% confidence interval (CI): 0·38–0·58%); 620 cases had IgG positivity (3·37%, 95% CI: 3·11–3·64%), and 650 cases had either IgG positivity or IgM positivity (3·53%, 95% CI: 3·26–3·80%). After standardizing for the genders and ages in the population of Wuhan, the overall standardized seroprevalence of IgG was 3·33% (95% CI: 3·07–3·59%) and the standardized seroprevalence of IgG was 3·01% (95% CI: 2·69–3·33%) among males and 3·66% (95 % CI: 3·23–4·09%) among females. The standardized seroprevalence of IgG was higher in women than in men with a significant difference (x 2 = 2060·3, p < 0·01). By a detection method adjustment, the seroprevalence of IgG was 1·57% (95% CI: 1·39–1·75%) in all medical records, of which males were 1·96% (95% CI: 1·64–2·28%), and females were 1·19% (95% CI: 0·99–1·39%). The assayadjusted seroprevalence of IgG was higher in women than in men, and the difference was significant (x 2 = 5871·0, p < 0·01). The differences were significant for seroprevalence of IgG among people who went back to work in different categories of work place (x 2 = 198·44, p < 0·01). The differences in seroprevalence for IgG positivity or IgM positivity among people who went back to work in different urban and rural areas was also significant (x 2 = 45·110, p < 0·01). Calculated as IgG and/or IgM antibody positivity, the number of new infections was reduced by 64·8% from March 26 to April 28, 2020. Based on the census population aged 16–64 years in Wuhan in 2017, we estimated that 172,340 (95% CI: 157,568–187,112) asymptomatic people aged 16–64 years were infected with SARS-CoV-2 in Wuhan between March 25 and April 28 2020. This estimate was 3·4-times higher than the officially reported 50,333 infections on April 28. Interpretation: The seropositivity rate in Wuhan indicated that RT-PCR-confirmed patients only represented a small part of the total number of cases. Seropositivity progressively decreased in the Wuhan population from March 26 to April 28, 2020, comparable to Japan and Denmark, but well below the level reported in New York, Iran, Italy, and Germany. The prevalence of asymptomatic infection was higher in women than in men among people who went back to work in Wuhan. The low seroprevalence suggests that most of the population remains susceptible to COVID19. Funding: Emergency Management Project of the National Natural Science Foundation of China (81842035) ; Advisory Research Project of the Chinese Academy of Engineering in 2019 (2019-XZ-70) Declaration of Interests: All authors declare no conflicts of interest. Ethics Approval Statement: This study was approved by the Ethics Committee of the Hubei Provincial Hospital of Integrated Chinese & Western Medicine. This was a retrospective and observational study and informed consent was obtained.

Background: Some cases retested positive for SARS-CoV-2 following negative testing results and discharge, which attracted widespread concern. However, the potential risk factors associated with re-detectable positive tests in a large sample of cases who recovered from COVID-19 has not been well estimated. Methods: A total of 745 discharged COVID-19 cases were enrolled between 30 January and 9 September 2020 in Guangzhou, China. Data on the clinical characteristics, comorbidities, drug therapy, RT-PCR testing, and contact modes to close contacts were collected. Re-positive cases were confirmed by guidelines issued by China. The re-positive rate of in different settings was calculated. Univariable and multivariable logistic regression models were used to explore the potential risk factors associated with COVID-19 re-positivity. Findings: Among 745 discharged cases, 157 (21.1%; 95%CI, 18.2% to 24.0%) were retested positive with 55 (35.0%) of asymptomatic, 15 (9.6%) of mild, 83 (52.9%) of moderate and 4 (2.6%) of severe at the first admission. The median time from discharge to re-positivity was 8.0 days (IQR, 8.0 to 14.0 days). Most re-positive cases were without clinical symptoms and lymphocyte cell counts increased than before. The likelihood of re-positive testing for SARS-CoV-2 RNA was significantly higher among cases with younger age (OR, 3.88; 95%CI, 1.74 to 8.66, 0 to 17 years old), asymptomatic severity (OR, 4.36; 95%CI, 1.47 to 12.95) and without clinical symptoms (OR, 1.89; 95%CI, 1.32 to 2.70, without fever). Interpretation: We found that the re-positive rate of COVID-19 was relatively high, and they were re-tested positive with median days 8.0 to 14.0 post-discharge. Re-positive results were mainly observed in young cases without severe clinical symptoms. These findings suggest that a significant proportion of cases could carry virus fragments for a long time, and effective management, such as prolonged quarantine phase of discharged cases, is necessary. Funding Statement: The Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; the Construction of High-level University of Guangdong; Young Elite Scientists Sponsorship Program by CAST; the National Natural Science Foundation of China; the Zhejiang University special scientific research fund for COVID-19 prevention and control. Declaration of Interests: We declare no competing interests. Ethics Approval Statement: This study was reviewed and approved by the Ethics Committee of GZCDC. As required by the National Health Commission of China, CDCs were responsible for the work for an ongoing public health response to COVID-19, and our cohort study was based on the data by GZCDC. Patients were informed about the surveillance before providing written consent, and data were collected and anonymized for analysis. All analysis of personally identifiable data took place onsite at the GZCDC.